GLENMARK

- Glenmark Pharmaceuticals Q2 results: Profit jumps 72% to ₹610.43 cr

Glenmark Pharmaceuticals Q2 results: Profit jumps 72% to ₹610.43 cr -

Glenmark Pharmaceuticals Ltd on Friday reported a 72.2 per cent jump in consolidated profit after tax at Rs 610.43 crore in the second quarter ended September 2025 on the back of its licensing deal with AbbVie for investigational asset 'ISB 2001'. The company had posted a consolidated profit after tax (PAT) of Rs 354.49 crore in the corresponding period last fiscal, Glenmark Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations was at Rs 6,046.87 crore as against Rs 3,433.8 crore in the same period a year ago, it added. Total expenses in the quarter under review were at Rs 3,894.98 crore as against Rs 3,000.64 crore in the same period last fiscal, the company said. All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24